Keros Therapeutics, Inc. (KROS) stock
KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$12.00+0.69 (+6.10%)
Close on Nov 18, 2026Market cap $237.93MP/E –Yield –
Keros Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Keros Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $14.54M, down 93.7% year over year. For fiscal 2025 it was $243.86M. The highest annual figure on record is $243.86M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $243.86M | – |
| FY2024 | Dec 31, 2024 | $0 | -100.0% |
| FY2023 | Dec 31, 2023 | $151.00K | – |
| FY2022 | Dec 31, 2022 | $0 | -100.0% |
| FY2021 | Dec 31, 2021 | $20.10M | – |
| FY2020 | Dec 31, 2020 | $0 | -100.0% |
| FY2019 | Dec 31, 2019 | $10.00M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | -100.0% |
| Q1 FY2026 | Mar 31, 2026 | $32.00K | -100.0% |
| Q4 FY2025 | Dec 31, 2025 | $380.00K | – |
| Q3 FY2025 | Sep 30, 2025 | $14.12M | – |
| Q2 FY2025 | Jun 30, 2025 | $18.17M | – |
| Q1 FY2025 | Mar 31, 2025 | $211.19M | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $0 | – |
| Q1 FY2024 | Mar 31, 2024 | $0 | – |
| Q4 FY2023 | Dec 31, 2023 | $143.00K | – |
| Q3 FY2023 | Sep 30, 2023 | $8.00K | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
| Q1 FY2023 | Mar 31, 2023 | $0 | -100.0% |
| Q4 FY2022 | Dec 31, 2022 | $0 | – |
| Q3 FY2022 | Sep 30, 2022 | $0 | -100.0% |
| Q2 FY2022 | Jun 30, 2022 | $0 | – |
| Q4 FY2021 | Dec 31, 2021 | $20.00M | – |
| Q3 FY2021 | Sep 30, 2021 | $0 | – |
| Q2 FY2021 | Jun 30, 2021 | $100.00K | – |
| Q4 FY2020 | Dec 31, 2020 | $0 | -100.0% |
| Q3 FY2020 | Sep 30, 2020 | $0 | -100.0% |
| Q2 FY2020 | Jun 30, 2020 | $0 | -100.0% |
| Q1 FY2020 | Mar 31, 2020 | $0 | -100.0% |
| Q4 FY2019 | Dec 31, 2019 | $2.50M | – |
| Q3 FY2019 | Sep 30, 2019 | $2.50M | – |
| Q2 FY2019 | Jun 30, 2019 | $2.50M | – |
| Q1 FY2019 | Mar 31, 2019 | $2.50M | – |
See a number that looks wrong?